---
title: "KCO: Sales rose but profitability declined in Q2 2026, with a strategic shift to value-added services"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294912642.md"
description: "Q2 2026 saw higher sales but lower gross profit and net income, mainly due to divestments and a significant write-down at Becker. The company is shifting toward higher value-added business, with net debt rising and EBITDA guidance for FY 2026 set at €170–250m.Original document: Kloeckner & Co SE [KCO] Slides Release — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-05T05:05:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294912642.md)
  - [en](https://longbridge.com/en/news/294912642.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294912642.md)
generator: "portal-rs"
---

# KCO: Sales rose but profitability declined in Q2 2026, with a strategic shift to value-added services

Q2 2026 saw higher sales but lower gross profit and net income, mainly due to divestments and a significant write-down at Becker. The company is shifting toward higher value-added business, with net debt rising and EBITDA guidance for FY 2026 set at €170–250m.

Original document: Kloeckner & Co SE \[KCO\] Slides Release — Aug. 5 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [KCO.DE](https://longbridge.com/en/quote/KCO.DE.md)

## Related News & Research

- [Klöckner voting rights: Ben Durham lifts stake to 5% from 3.17%](https://longbridge.com/en/news/295806444.md)
- [Russel Metals posts investor deck highlighting record revenue and shipments in Q2 2026](https://longbridge.com/en/news/295693263.md)
- [BEWI: Q2 2026 delivered double-digit sales and EBITDA growth, with strong performance across all segments](https://longbridge.com/en/news/296303987.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**